Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation

Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced positive topline results from the US Phase 3 ...

Leqembi® approved for the treatment of early Alzheimer's disease in Australia

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved lecanemab (Leqembi) for the treatment of adult patients with ...
RMD Open

Serum calprotectin and complement factor C3 are superior biomarkers of inflammation in early psoriatic arthritis as compared with C-reactive protein

Objectives C reactive protein (CRP) is frequently normal in psoriatic arthritis (PsA) despite active disease, complicating ...
Lupus Science & Medicine

Association of disease-modifying antirheumatic drug selection with hospitalised infection among youth with childhood-onset systemic lupus erythematosus

Objective Youth with childhood-onset SLE (cSLE) have increased risk of serious infection. It is unknown how much of this risk ...
Lupus Science & Medicine

Towards a minimal core dataset for systemic lupus erythematosus studies

Objective SLE is a complex, heterogenous autoimmune disease. SLE researchers do not always collect the same data, making ...